{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:39:22Z","timestamp":1781779162299,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":510,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (VYNDAQEL\u00ae) in Japan using the Japanese Medical Data Vision (MDV) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This study was a non-interventional, retrospective cohort study of adult (\u226518 years old) patients in the Japanese MDV claims database diagnosed with ATTR-CM and with at least two tafamidis prescriptions of dose strength 4 \u00d7 20 mg\/day between 1 March 2019 and 31 August 2021. The date of the first prescription was defined as the index date, with follow-up time defined as the time between the first and last prescription plus the days' supply from the last refill. Baseline characteristics were assessed during a 12 month pre-index period. Adherence was measured using two metrics: (i) the modified medication possession ratio (mMPR), calculated by taking the sum of days supplied for all fills within the follow-up period, divided by the number of days of follow-up, and reported as a percentage, with patients classified as adherent with an mMPR of \u226580%, and (ii) the proportion of days covered (PDC), calculated by taking the total number of days' supply dispensed during the follow-up period divided by the number of days of follow-up, adjusting for any days' supply overlap. A total of 210 patients were identified; the mean (standard deviation) age of the cohort was 77 (5.9) years, and the majority (89%) were male. The most common baseline cardiovascular comorbidities were heart failure (85%), ischaemic heart disease (66%), hypertensive diseases (49%), and diabetes (35%); 75% of patients received heart failure medications in the 12 months prior to index, with the most common being beta-blockers (49%), diuretics (48%), angiotensin receptor blockers (30%), angiotensin-converting enzyme inhibitors (22%), and sodium\u2013glucose cotransporter-2 inhibitors (8.1%). Over an average 14 month follow-up, mean mMPR was 96% with a median of 100% [inter-quartile range (IQR): 97\u2013101%]; 93% of patients were adherent (defined as an mMPR \u2265 80%). In the same follow-up period, mean PDC was 93.6% with a median of 99% (IQR: 93\u2013100%). Persistence was high with 78% of patients having a 0 day gap between prescription refills.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study found high adherence rates to tafamidis in this real-world Japanese patient population. Adherence rates in this study were similar to those reported by the tafamidis clinical trial and a previously published US commercial claims adherence analysis. Further studies should be conducted to assess the impact of real-world adherence on real-world outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14736","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:49:12Z","timestamp":1716511752000},"page":"2881-2888","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tafamidis Medication Adherence and Persistence in Patients with Transthyretin Amyloid Cardiomyopathy in Japan"],"prefix":"10.1093","volume":"11","author":[{"given":"Takao","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ines","sequence":"additional","affiliation":[{"name":"Pfizer Portugal , Porto Salvo ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Minamisawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine , Matsumoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1863","authenticated-orcid":false,"given":"Darrin","family":"Benjumea","sequence":"additional","affiliation":[{"name":"Genesis Research Group , Hoboken, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Keohane","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alvir","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Kim","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Collegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Telma","family":"Peixoto","sequence":"additional","affiliation":[{"name":"Pfizer Portugal , Porto Salvo ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kent","sequence":"additional","affiliation":[{"name":"Genesis Research Group , Hoboken, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenifer","family":"Wogen","sequence":"additional","affiliation":[{"name":"Genesis Research Group , Hoboken, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Crowley","sequence":"additional","affiliation":[{"name":"Genesis Research Group , Hoboken, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Sugino","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"2026012113131350700_ehf214736-bib-0001","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coph.2005.10.005","article-title":"Systemic amyloidosis","volume":"6","author":"Lachmann","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"2026012113131350700_ehf214736-bib-0002","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): A review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J Intern Med"},{"key":"2026012113131350700_ehf214736-bib-0003","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"key":"2026012113131350700_ehf214736-bib-0004","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"key":"2026012113131350700_ehf214736-bib-0005","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: An update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Cleve Clin J Med"},{"key":"2026012113131350700_ehf214736-bib-0006","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/hrt.2009.190405","article-title":"Amyloid diseases of the heart: Assessment, diagnosis, and referral","volume":"97","author":"Dubrey","year":"2011","journal-title":"Heart"},{"key":"2026012113131350700_ehf214736-bib-0007","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113131350700_ehf214736-bib-0008","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/cir.0000000000000792","article-title":"Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026012113131350700_ehf214736-bib-0009","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012113131350700_ehf214736-bib-0010","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: Insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012113131350700_ehf214736-bib-0011","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/circulationaha.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2026012113131350700_ehf214736-bib-0012","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012113131350700_ehf214736-bib-0013","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.pcad.2013.02.001","article-title":"Adherence to cardiovascular medications: Lessons learned and future directions","volume":"55","author":"Kronish","year":"2013","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012113131350700_ehf214736-bib-0014","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejca.2017.04.003","article-title":"Real-world data for efficient health technology assessment","volume":"79","author":"Hall","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026012113131350700_ehf214736-bib-0015","volume-title":"Adherence to Long-Term Therapies: Evidence for Action","author":"Sabat\u00e9","year":"2003"},{"key":"2026012113131350700_ehf214736-bib-0016","first-page":"437","article-title":"Medicaid beneficiaries with congestive heart failure: Association of medication adherence with healthcare use and costs","volume":"15","author":"Esposito","year":"2009","journal-title":"Am J Manag Care"},{"key":"2026012113131350700_ehf214736-bib-0017","doi-asserted-by":"publisher","first-page":"705","DOI":"10.18553\/jmcp.2019.25.6.705","article-title":"Prescription drug spending and medication adherence among Medicare beneficiaries with heart failure","volume":"25","author":"McGee","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2026012113131350700_ehf214736-bib-0018","doi-asserted-by":"publisher","first-page":"766","DOI":"10.18553\/jmcp.2022.28.7.766","article-title":"Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and\/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort","volume":"28","author":"Roy","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2026012113131350700_ehf214736-bib-0019","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/ppa.S352332","article-title":"Baseline characteristics and secondary medication adherence patterns among patients receiving tafamidis prescriptions: A retrospective analysis using a national specialty pharmacy dispensing database","volume":"16","author":"Roy","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"2026012113131350700_ehf214736-bib-0020","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/00019053-199304050-00003","article-title":"The role of insurance claims databases in drug therapy outcomes research","volume":"4","author":"Lewis","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2026012113131350700_ehf214736-bib-0021","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"2026012113131350700_ehf214736-bib-0022","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","article-title":"Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med Care"},{"key":"2026012113131350700_ehf214736-bib-0023","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.016215","article-title":"Difference in medication adherence between patients prescribed a 30-day versus 90-day supply after acute myocardial infarction","volume":"10","author":"Rymer","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026012113131350700_ehf214736-bib-0024","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012113131350700_ehf214736-bib-0025","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/PPA.S110147","article-title":"Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan","volume":"10","author":"Mahlich","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2026012113131350700_ehf214736-bib-0026","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1742-1241.2007.01630.x","article-title":"The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review","volume":"62","author":"Cramer","year":"2008","journal-title":"Int J Clin Pract"},{"key":"2026012113131350700_ehf214736-bib-0027","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025806","article-title":"Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: A claims-based cohort study","volume":"9","author":"Nishimura","year":"2019","journal-title":"BMJ Open"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2881\/64515488\/eschf_11_5_2881.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2881\/64515488\/eschf_11_5_2881.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:59Z","timestamp":1769019299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/5\/2881\/8271123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,23]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14736","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"2023-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}